Senior/Research Associate, Functional Genomics

NewLimit; South San Francisco (CA); On-site; USD 75,000 - 100,000; Full time

Benefits offered by this job

Health, dental, and vision insurance

401(k) with company match

Paid parental leave

20 days PTO

Job summary

NewLimit in South San Francisco is seeking a Senior/Research Associate with a Bachelor's degree in cell biology or molecular biology. Responsibilities include collaborating on large-scale single cell experiments, building recombinant DNA vectors, and applying viral vectors to cell lines. Ideal candidates have 2+ years in a lab setting and experience with molecular cloning and cell culture. The position offers a salary range of $75,000 to $100,000 and extensive benefits including health insurance and 20 days PTO.

Qualifications

• 2+ years of work experience in a cell or molecular biology laboratory.
• Experience with molecular cloning, nucleic acid analysis, and related methods.
• Experience with mammalian cell culture.

Responsibilities

• Collaborate on large-scale single cell experiments with custom chemistries.
• Build recombinant DNA vectors for perturbation experiments.
• Prepare and apply viral vectors to mammalian cell lines.

Skills

Molecular cloning

Nucleic acid analysis

Mammalian cell culture

Education

Bachelor’s degree in cell biology or molecular biology

Tools

RT-qPCR

Gel electrophoresis

FACS or flow cytometry

Job description

About NewLimit

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age‑related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Position

We are seeking a Senior/Research Associate with experience in molecular biology to join our Epigenetic Editing group. Pooled screening technologies are at the heart of our discovery engine, allowing us to rapidly search for epigenetic reprogramming therapies that restore cell function and reduce the burden of disease.

As a Member Of Our Team, You Will

• Collaborate with our Single Cell Technology team to implement large‑scale, single cell perturbation experiments with custom chemistries
• Build recombinant DNA vectors by synthesis and cloning to enable large‑scale single cell perturbation experiments
• Prepare, titer, and apply viral vectors (lentiviral, AAV) to transduce mammalian cell lines and primary cells
• Contribute to scaling and improving pooled single cell perturbation screens

Requirements

• Bachelor’s degree in cell biology, molecular biology, or a related natural science or industry experience
• 2+ years of work experience in a cell or molecular biology laboratory (academic or industry)
• Experience with molecular cloning, nucleic acid analysis (RT‑qPCR, gel electrophoresis), and related molecular biology methods
• Experience with mammalian cell culture

Nice to Have

• Experience with next‑generation sequencing assays and functional genomics
• Experience with FACS or flow cytometry
• Computational skills for next‑generation sequencing analysis (Python programming, Unix)
• Experience with single cell genomics methods
• Experience with epigenetic reprogramming methods for cell fate engineering or targeted epigenetic editing

Benefits

• Health, dental, and vision insurance
• 401(k) with company match
• Paid parental leave
• Industry‑leading paid time off (PTO) – 20 days per year for all employees + holidays
• Meals and snacks on‑site

Salary Range: $75,000 to $100,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401(k), healthcare coverage, and 20 days of PTO.

Learn more at: https://www.newlimit.com/careers
*This compensation and benefits information is based on Company’s good faith estimate as of the date of publication and may be modified in the future.